# **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on May 19, 2025

# Phospho-4E-BP1 (Ser65) (D9G1Q)

RRID:AB\_2728761 Type: Antibody

### **Proper Citation**

(Cell Signaling Technology Cat# 13443, RRID:AB\_2728761)

## Antibody Information

URL: http://antibodyregistry.org/AB\_2728761

Proper Citation: (Cell Signaling Technology Cat# 13443, RRID:AB\_2728761)

Target Antigen: Phospho-4E-BP1 (Ser65)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: Phospho-4E-BP1 (Ser65) (D9G1Q)

Description: This monoclonal targets Phospho-4E-BP1 (Ser65)

Target Organism: monkey, human

Antibody ID: AB\_2728761

Vendor: Cell Signaling Technology

Catalog Number: 13443

**Record Creation Time:** 20231110T033636+0000

Record Last Update: 20240725T061252+0000

**Ratings and Alerts** 

No rating or validation information has been found for Phospho-4E-BP1 (Ser65) (D9G1Q).

No alerts have been found for Phospho-4E-BP1 (Ser65) (D9G1Q).

#### Data and Source Information

Source: Antibody Registry

#### **Usage and Citation Metrics**

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Remy D, et al. (2024) TFEB triggers a matrix degradation and invasion program in triplenegative breast cancer cells upon mTORC1 repression. Developmental cell.

Cao Y, et al. (2023) Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors. Cell reports, 42(7), 112764.

Ohata H, et al. (2023) PROX1 induction by autolysosomal activity stabilizes persister-like state of colon cancer via feedback repression of the NOX1-mTORC1 pathway. Cell reports, 42(6), 112519.

Ebner M, et al. (2023) Nutrient-regulated control of lysosome function by signaling lipid conversion. Cell, 186(24), 5328.

Zhang Y, et al. (2021) Himalaquinones A-G, Angucyclinone-Derived Metabolites Produced by the Himalayan Isolate Streptomyces sp. PU-MM59. Journal of natural products, 84(7), 1930.

Xiao B, et al. (2020) Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. Cell reports, 31(4), 107571.

Ye Q, et al. (2019) Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell chemical biology, 26(3), 366.

Ohata H, et al. (2019) NOX1-Dependent mTORC1 Activation via S100A9 Oxidation in Cancer Stem-like Cells Leads to Colon Cancer Progression. Cell reports, 28(5), 1282.